title: HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
abstract: Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.
authors.affiliation: Division of Hematology & Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL 32224, USA.
authors.forename: Pooja P
authors.initials: PP
authors.lastname: Advani
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Crozier
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D009360:Neoplastic Cells, Circulating / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases
keywords: American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines; HER2 testing; breast cancer; immunohistochemistry (IHC); in situ hybridization (ISH); trastuzumab